Oncogenic re-wiring of cellular signaling pathways

Oncogene

Volumn 26, Issue 9, 2007, Pages 1268-1275

  Pawson, T ^a,b   Warner, N ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Domains; Fusion proteins; Protein protein interactions

Indexed keywords

BCR ABL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN SH2; PROTEIN TYROSINE KINASE; RETINOIC ACID RECEPTOR ALPHA;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; AUTOREGULATION; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; GENE AMPLIFICATION; GENE MUTATION; HUMAN; MALIGNANT TRANSFORMATION; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LIPID INTERACTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; ONCOGENES; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 33847285870     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210255     Document Type: Review

References (44)

1. Aghazadeh B, Lowry WE, Huang XY, Rosen MK. (2000). Structural basis for relief of autoinhibition of the Dbl homology domain of proto-oncogene Vav by tyrosine phosphorylation. Cell 102: 624-633.
2. Anderson D, Koch CA, Grey L, Ellis C,MoranMF, Pawson T. (1990). Binding of SH2 domains of phospholipase Cγ1, GAP, and Src to activated growth factor receptors. Science 250: 979-982.
3. Bhattacharyya RP, Remenyi A, Yeh BJ, Lim WA. (2006). Domains, motifs, and scaffolds: the role of modular interactions in the evolution and wiring of cell signaling circuits. Annu Rev Biochem 75: 655-680.
4. Bilder D. (2004). Epithelial polarity and proliferation control: links from the Drosophila neoplastic tumor suppressors. Genes Dev 18: 1909-1925.
5. Brown MT, Cooper JA. (1996). Regulation, substrates and functions of Src. Biochem Biophys Acta 1287: 121-149.
6. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS et al. (1999). Akt promotes cell survival by phosphoylating and inhibiting a forkhead transcription factor. Cell 96: 857-868.
7. Bustelo XR. (2000). Regulatory and signaling properties of the Vav family. Mol Cell Biol 20: 1461-1477.
8. Dueber JE, Yeh BJ, Chak K, Lim WA. (2003). Reprogramming control of an allosteric signaling switch through modular recombination. Science 301: 1904-1908.
9. Engelman JA, Luo J, Cantley LC. (2006). The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7: 606-619.
10. Frischknecht F, Moreau V, Rottger S, Gonfloni S, Reckmann I, Superti-Furga G et al. (1999). Actin-based motility of vaccinia virus mimics receptor tyrosine kinase signalling. Nature 401: 926-929.
11. Gruenheid S, DeVinney R, Bladt F, Goosney D, Gelkop S, Gish GD et al. (2001). Enteropathogenic E. coli Tir binds Nck to initiate actin pedestal formation in host cells. Nat Cell Biol 3: 856-859.
12. Haglund K, Dikic I. (2005). Ubiquitylation and cell signaling. EMBO J 24: 3353-3359.
13. He Y, Wertheim JA, XuL, Miller JP, Karnell FG, Choi JK et al. (2002). The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl. Blood 99: 2957-2968.
14. Heldin CH. (1995). Dimerization of cell surface receptors in signal transduction. Cell 80: 213-223.
15. Howard PL, Chia MC, Del Rizzo S, LiuF-F, Pawson T. (2003). Re-directing tyrosine kinase signaling to an apoptotic caspase pathway through chimeric adaptor proteins. Proc Natl Acad Sci USA 100: 11267-11272.
16. Hu J, Liu J, Ghirlando R, Saltiel AR, Hubbard SR. (2003). Structural basis for recruitment of the adaptor protein APS to the activated insulin receptor. Mol Cell 12: 1379-1389.
17. Hubbard SR. (1997). Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J 16: 5572-5581.
18. Hubbard SR, Till JH. (2000). Protein tyrosine kinase structure and function. Annu Rev Biochem 69: 373-398.
19. Hunter T. (2000). Signaling - 2000 and beyond. Cell 100: 113-127.
20. Jones RB, Gordus A, Krall JA, Macbeath G. (2006). A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 439: 168-174.
21. Kim AS, Kakalis LT, Abdul-Manan N, Liu GA, Rosen MK. (2000). Autoinhibition and activation mechanisms of the Wiskott-Aldrich syndrome protein. Nature 404: 151-158.
22. Kim JH, Chu SC, Gramlich JL, Pride YB, Babendreier E, Chauhan D et al. (2005). Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood 105: 1717-1723.
23. Kong-Beltran M, Seshagiri S, Zha J, ZhuW, Bhawe K, Mendoza N et al. (2006). Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 66: 283-289.
24. Liu BA, Jabonowski K, Raina M, Arce M, Pawson T, Nash PD. (2006). The human and mouse complement of SH2 domain proteins - establishing the boundaries of phosphotyrosine signaling. Mol Cell 22: 851-868.
25. Llorca O, Arias-Palomo E, Zugaza L, Bustelo XR. (2005). Global conformational rearrangements during the activation of the GDP/GTP exchange factor Vav3. EMBO J 24: 1330-1340.
26. Macara IG. (2004). Parsing the polarity code. Nat Rev Mol Cell Biol 5: 220-231.
27. McWhirter JR, Galasso DL, Wang JY. (1993). A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol 13: 7587-7595.
28. Million RP, Van Etten RA. (2000). The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. Blood 96: 664-670.
29. Minucci S, Nervi C, Lo Coco F, Pelicci PG. (2001). Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias. Oncogene 20: 3110-3115.
30. Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W et al. (2003). Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112: 859-872.
31. Pawson T, Nash P. (2000). Protein-protein interactions define specificity in signal transduction. Genes Dev 14: 1027-1047.
32. Pawson T, Nash P. (2003). Assembly of cell regulatory systems through protein interaction domains. Science 300: 445-452.
33. Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N et al. (1993). BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75: 175-185.
34. Puil L, Liu X, Gish G, Mbamalu G, Bowtell D, Pelicci PG et al. (1994). BCR-ABL oncoproteins bind directly to activators of the ras signalling pathway. EMBO J 13: 764-773.
35. Rowley JD. (1990). The Philadelphia chromosome translocation. A paradigm for understanding leukemia. Cancer 65: 2178-2184.
36. Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K et al. (2002). Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 1: 479-492.
37. Sicheri F, Moarefi I, Kuriyan J. (1997). Crystal structure of the Src family tyrosine kinase Hck. Nature 385: 602-609.
38. Thomas M, Massimi P, Navarro C, Borg JP, Banks L. (2005). The hScrib/Dig apico-basal control complex is differentially targeted by HPV-16 and HPV-18 E6 proteins. Oncogene 24: 6222-6230.
39. Weinmaster G, Zoller MJ, Smith M, Hinze E, Pawson T. (1984). Mutagenesis of Fujinami sarcoma virus: evidence that tyrosine phosphorylation of P130gap-fps modulates its biological activity. Cell 37: 559-568.
40. Xu W, Harrison SC, Eck MJ. (1997). Three-dimensional structure of the tyrosine kinase c-Src. Nature 385: 595-602.
41. Zarrinpar A, Bhattacharyya RP, Lim WA. (2003). The structure and function of proline recognition domains. Sci STKE, 2003. RE8.
42. L. Cell 87: 619-628.
43. Zhou J, Peres L, Honore N, Nasr R, Zhu J, de The H. (2006). Dimerization-induced corepressor binding and relaxed DNA-binding specificity are critical for PML/RARA-induced immortalization. Proc Natl Acad Sci USA 103: 9238-9243.
44. Zhu J, Zhou J, Peres L, Riaucoux F, Honore N, Kogan S et al. (2005). A sumoylation site in PML. RARA is essential for leukemic transformation. Cancer Cell 7: 143-153.